Antiatherosclerotic and cardioprotective effects of Time-released garlic powder pills

Current Pharmaceutical Design

Volumn 22, Issue 2, 2015, Pages 196-213

  Karagodin, Vasily P ^a,b   Sobenin, Igor A ^c,d   Orekhov, Alexander N ^b,d  

^a PLEKHANOV RUSSIAN UNIVERSITY OF ECONOMICS   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d Skolkovo Innovation Center   (Russian Federation)

Author keywords

Allicor; Atherosclerosis; Coronary heart disease; Garlic; Prevention; Treatment

Indexed keywords

CARDIOTONIC AGENT;

CORONARY ARTERY DISEASE; DIETARY SUPPLEMENT; DRUG FORMULATION; GARLIC; HUMAN; PHYTOTHERAPY;

CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DRUG COMPOUNDING; GARLIC; HUMANS; PHYTOTHERAPY;

EID: 84960947885     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151112153351     Document Type: Article

References (167)

1. Prasad K. Natural products in regression and slowing of progression of atherosclerosis. Curr Pharm Biotechnol 2010; 11: 794-800.
2. Orekhov AN, Sobenin IA, Korneev NV, et al. Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov 2013; 8: 56-66.
3. El-Sayyad HI, Abou-El-Naga AM, Gadallah AA, Bakr IH. Protective effects of Allium sativum against defects of hypercholesterolemia on pregnant rats and their offspring. Int J Clin Exp Med 2010; 3: 152-63.
4. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Int Med 2014; 6(276): 618-32.
5. Sobenin IA, Andrianova IV, Fomchenkov IV, Gorchakova TV, Orekhov AN. Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. Hypertens Res 2009; 32: 433-7.
6. Sobenin IA, Andrianova IV, Demidova ON, Gorchakova TV, Orekhov AN. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. J Atheroscler Thromb 2008; 15: 334-8.
7. Jiang X, Yang Z, Chandrakala AN, Pressley D, Parthasarathy S. Oxidized low density lipoproteins-do we know enough about them? Cardiovasc Drugs Ther 2011; 25: 367-77.
8. Weber C, Noels H. Atherosclerosis. Current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-22.
9. Yuan Y, Li P, Ye J. Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis. Protein Cell 2012; 3: 173-81.
10. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011; 22: 254-61.
11. Orekhov AN. Intracellular cholesterol retention-new target for direct anti-atherosclerotic therapy. Open J Endocr Metabol Dis 2013; 3: 9-17.
12. Orekhov AN, Tertov VV, Kudryashov SA, et al. Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res 1990; 66: 311-20.
13. Orekhov AN, Andreeva ER, Mikhailova IA, et al. Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis 1998; 139: 41-8.
14. Wolf D, Stachon P, Bode C, Zirlik A. Inflammatory mechanisms in atherosclerosis. Hastaseologie 2014; 34(1): 63-71.
15. Fowkes, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329-40.
16. Chazov EI, Tertov VV, Orekhov AN, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.
17. Tertov VV, Orekhov AN, Martsenyuk ON, et al. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989; 50: 337-47.
18. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992; 67: 665-75.
19. Tertov VV, Sobenin IA, Orekhov AN. Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation. Int J Tissue React 1992; 14: 155-62.
20. Orekhov AN, Tertov VV, Lyakishev AA, et al. Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists. J Hum Hypertens 1991; 5: 425-30.
21. Orekhov AN, Tertov VV, Sobenin IA, et al. Direct antiatherosclerosis-related effects of garlic. Ann Med 1995; 27: 63-5.
22. Orekhov AN, Grunwald J. Effects of garlic on atherosclerosis. Nutrition 1997; 13: 656-63.
23. Orekhov AN, Tertov VV. In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids 1997; 32: 1055-60.
24. Simmons A, Steffen K, Sanders S. Medical therapy for peripheral arterial disease. Curr Opin Cardiol 2012; 27(6): 592-7.
25. Ried K, Fakler P. Potential of garlic (Allium sativum) in lowering high blood pressure: mechanisms of action and clinical relevance. Integr Blood Press Control 2014; 7: 71-82.
26. Rohner A, Ried K, Sobenin IA, Bucher HC, Nordmann AJ. A systematic review and meta-analysis on the effects of garlic preparations on blood pressure in individuals with hypertension. Am J Hypertens 2015; 3: 414-23.
27. Neil HA, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and metaanalysis. J R Coll Phys Lond 1996; 30: 329-34.
28. Steiner M, Khan AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr 1996; 64: 866-70.
29. Hopkins AL, Lamm MG, Funk JL, Ritenbaugh C. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. Fitoterapia 2013; 85(1): 84-94.
30. Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters. A sys-tematic review and meta-analysis. Nutr Res Rev 2009; 22: 39-48.
31. Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metabol Clin North Am 2014; 43: 1007-33.
32. Ried K, Toben C, Fakler P. Effect of garlic on serum lipids. an updated meta-analysis. Nutr Rev 2013; 71: 282-99.
33. Ried K, Toben C, Fakle P. Effect of garlic on serumlipids: an updated meta-analysis. Nutr Rev 2013; 71(5): 282-99.
34. Rahman K. Historical perspective on garlic and cardiovascular disease. J Nutr 2001; 131: 977S-9S.
35. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am 2012; 96: 13-26.
36. Rai AK, Debetto P, Sala FD. Molecular regulation of cholesterol metabolism: HDL-based intervention through drugs and diet. Ind J Exp Biol 2013; 51(11): 885-94.
37. Simons LA, Balasubramaniam S, von K, Parfitt A, Simons J, Peters W. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia. Atherosclerosis 1995; 113: 219-25.
38. Silagy C, Neil A. Garlic as a lipid lowering agent-a meta-analysis. J R Coll Phys Lond 1994; 28: 39-45.
39. Issacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomised, placebocontrolled trial. Arch Intern Med 1998; 158: 1189-94.
40. Berthold HK, Sudhop T. Garlic preparations for prevention of atherosclerosis. Curr Opin Lipidol 1998; 9: 565-9.
41. Block E. The chemistry of garlic and onions. Sci Am 1985; 252: 114-9.
42. Lawson LD, Ransom DK, Hughes BG. Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial products. Thromb Res 1992; 65: 141-56.
43. Newall CA, Anderson LA, Phillipson JD. Garlic. In: Newall CA, Anderson LA, Phillipson JD, Eds. Herbal Medicines-A Guide for Health Care Professionals. Cambridge, UK: University Press 1995; vol. 3: pp. 129-33.
44. Iberl B., Winkler G., Muller B., Knobloch K. Quantitative determination of allicin and alliin from garlic by HPLC. Planta Med 1990; 56: 320-26.
45. Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. J Nutr 2001; 131: 955S-62S.
46. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis-related effects of garlic. Ann Med 1995; 27: 63-5.
47. Andrianova IV, Ionova VG, Demina EG, et al. Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases. Klin Med (Mosk) 2001; 79: 55-8.
48. Orekhov AN. New prospects for the treatment of atherosclerosis: garlic preparations. Ter Arkh 1998; 70: 75-8.
49. Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 2010; 9: 119.
50. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis-related efects of garlic. Ann Med 1995; 27: 63-5.
51. Foushee DB, Ruffin J, Banerjee U. Garlic as a natural agent for the treatment of hypertension: a preliminary report. Cytobios 1982; 34: 145-52.
52. Mayeux PR, Agrawal KC, Tou JS, et al. The pharmacological effects of allicin, a constituent of garlic oil. Agents Actions 1988; 25: 182-90.
53. Orekhov AN. New prospects for the treatment of atherosclerosis: garlic preparations. Ter Arkh 1998; 70: 75-8.
54. Martin N, Bardisa L, Pantoja CV, Roman R, Vargas M. Experimental cardiovascular depressant effects of garlic (Allium sativum) dialysate. J Ethnopharmacol 1992; 37: 145-9.
55. Kaye AD, Nossaman BD, Ibrahim IN, et al. Analysis of responses of allicin, a compound from garlic, in the pulmonary vascular bed of the cat and in the rat. Eur J Pharmacol 1995; 276: 21-6.
56. Al Qattan KK, Alnaqeeb MA, Ali M. The antihypertensive effect of garlic (Allium sativum) in the rat two-kidney-one-clip Goldblatt model. J Ethnopharmacol 1999; 66: 217-22.
57. Al Qattan KK, Khan I, Alnaqeeb MA, Ali M. Thromboxane-B2, prostaglandin-E2 and hypertension in the rat 2-kidney 1-clip model: a possible mechanism of the garlic induced hypotension. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 5-10.
58. Brandle M, A Makdessi, Weber RK, Dietz K, Jacob R. Prolongation of life span in hypertensive rats by dietary interventions. Effects of garlic and linseed oil. Basic Res Cardiol 1997; 92: 223-32.
59. Elkayam A, Mirelman D, Peleg E, et al. The effects of allicin and enalapril in fructose-induced hyperinsulinemic hyperlipidemic hypertensive rats. Am J Hypertens 2001; 14: 377-81.
60. Fallon MB, Abrams GA, Abdel R, et al. Garlic prevents hypoxic pulmonary hypertension in rats. Am J Physiol 1998; 275: L283-7.
61. Campbell JH, Efendy JL, Smith NJ, Campbell GR. Molecular basis by which garlic suppresses atherosclerosis. J Nutr 2001; 131: 1006S-9S.
62. Pedraza C, Tapia E, Medina C, de los A, Franco M. Garlic prevents hypertension induced by chronic inhibition of nitric oxide synthesis. Life Sci 1998; 62: L71-7.
63. Mohamadi A, Jarrell ST, Shi SJ, et al. Effects of wild versus cultivated garlic on blood pressure and other parameters in hypertensive rats. Heart Dis 2000; 2: 3-9.
64. Getz GS, Reardon CA. Animal models of atherosclerosis. Arteriosclerosis, Thromb Vasc Biol 2012; 32: 1104-15.
65. Peng X. Transgenic rabbit models for studying human cardiovascular diseases. Comparat Med 2012; 62(6): 472-9.
66. Fei W, Tong T, Yifeng P, Jingli T, et al. A modified rabbit model of carotid atherosclerotic plaque suitable for the stroke study and MRI evaluation. Int J Neurosci 2011; 121: 662-9.
67. Pantoja CV, Chiang LC, Norris BC, Concha JB. Diuretic, natriuretic and hypotensive effects produced by Allium sativum (garlic) in anaesthetized dogs. J Ethnopharmacol 1991; 31: 325-31.
68. Pantoja CV, Norris BC, Contreras CM. Diuretic and natriuretic effects of chromatographically purified fraction of garlic (Allium sativum). J Ethnopharmacol 1996; 52: 101-5.
69. Pantoja CV, Martin NT, Norris BC, Contreras CM. Purification and bioassays of a diuretic and natriuretic fraction from garlic (Allium sativum). J Ethnopharmacol 2000; 70: 35-40.
70. Siegel G, Walter A, Schnalke F, et al. Potassium channel activation, hyperpolarization, and vascular relaxation. Z Kardiol 1991; 80: S9-24.
71. Schulman IH, Zachariah M, Raij L. Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005; 17(4): 40-5.
72. Donnell CJ, Kannel WB. Cardiovascular risks of hypertension: lessons from observational studies. J Hypertens 1998; 16: S3-7.
73. Kannel WB. Review of recent Framingham study hypertension research. Curr Hypertens Rep 2000; 2: 239-40.
74. Kato J, Aihara A, Kikuya M, et al. Risk factors and predictors of coronary arterial lesions in japanese hypertensive patients. Hypertens Res 2001; 24: 3-11.
75. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7.
76. Orekhov AN. Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention. Curr Pharm Des 2013; 19(33): 5909-28.
77. Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostagland Leukot Essent Fatty Acids 1998; 58: 257-63.
78. Chutani SK, Bordia A. The effect of fried versus raw garlic on fibrinolytic activity in man. Atherosclerosis 1981; 38: 417-21.
79. Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostagland Leukot Essent Fatty Acids 1996; 55: 201-5.
80. Kiesewetter H, Jung F, Jung EM, et al. Effects of garlic coated tablets in peripheral arterial occlusive disease. Clin Investig 1993; 71: 383-6.
81. Ali M. Mechanism by which garlic (Allium sativum) inhibits cyclooxygenase activity. Effect of raw versus boiled garlic extract on the synthesis of prostanoids. Prostagland Leukot Essent Fatty Acids 1995; 53: 397-400.
82. Ali M, Mohammed SY. Selective suppression of platelet thromboxane formation with sparing of vascular prostacyclin synthesis by aqueous extract of garlic in rabbits. Prostaglandins Leukot Med 1986; 25: 139-46.
83. Srivastava KC. Evidence for the mechanism by which garlic inhibits platelet aggregation. Prostagland Leukot Med 1986; 22: 313-21.
84. Ali M, Thomson M, Alnaqeeb MA, A Hassan, Khater SH, Gomes SA. Antithrombotic activity of garlic: its inhibition of the synthesis of thromboxane-B2 during infusion of arachidonic acid and collagen in rabbits. Prostagland Leukot Essent Fatty Acids 1990; 41: 95-9.
85. Bordia T, Mohammed N, Thomson M, Ali M. An evaluation of garlic and onion as antithrombotic agents. Prostagland Leukot Essent Fatty Acids 1996; 54: 183-6.
86. Mohammad SF, Woodword SC. Characterization of a potent inhibitor of platelet aggregation and release reaction isolated allium sativum (garlic). Thromb Res 1986; 44: 793-806.
87. Makheja AN, Bailey JM. Antiplatelet constituents of garlic and onion. Agents Actions 1990; 29: 360-3.
88. Kiesewetter H, Jung F, Mrowietz C, et al. Effects of garlic on blood fluidity and fibrinolytic activity: a randomised, placebocontrolled, double-blind study. Br J Clin Pract Suppl 1990; 69: 24-9.
89. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LM, Christlieb AR. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1990; 90: 56S-61S.
90. Burchfiel CM, Reed DM, Marcus EB, Strong JP, Hayashi T. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. Am J Epidemiol 1993; 137: 1328-40.
91. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
92. Sobenin IA, Nedosugova LV, Filatova LV, Balabolkin MI, Gorchakova TV, Orekhov AN. Metabolic effects of timereleased garlic powder tablets in type 2 diabetes mellitus: the results of doubleblinded placebocontrolled study. Acta Diabetol 2008; 45(1): 1-6.
93. Swanston-Flatt SK, Flatt PR, Day C, Bailey CJ. Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc 1991; 50: 641-51.
94. Kirk JK, Davis SW, Hildebrandt CA, Strachan EN, Peechara ML, Lord R. Characteristics associated with glycemic control among family medicine patients with type 2 diabetes. N C Med J 2011; 72: 345-50.
95. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 1998; 88: 765-70.
96. Goraya TY, Leibson CL, Palumbo PJ. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002; 40: 946-53.
97. Nesto RW, Rutter MK. Impact of the atherosclerotic process in patients with diabetes. Acta Diabetol 2002; 39(2): S22-8.
98. Koskinen P, Irjala K, Viikari J, Panula O, Matikainen MT. Serum fructosamine in the assessment of glycaemic control in diabetes mellitus. Scand J Clin Lab Invest 1989; 47: 285-92.
99. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011; 22: 254-61.
100. Wiklund O, Witztum JL, Carew TE, Pittman RC, Elam RL, Steinberg D. Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J Lipid Res 1987; 28: 1098-109.
101. Witztum JL, Koschinsky T. Metabolic and immunological consequences of glycation of low density lipoproteins. Prog Clin Biol Res 1989; 304: 219-34.
102. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938-41.
103. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-8.
104. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
105. Mathew PT, Augusti KT. Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes. I. Hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis. Indian J Biochem Biophys 1973; 10: 209-12.
106. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011; 22: 254-61.
107. Jain RC, Vyas CR. Hypoglycaemia action of onion on rabbits. Br Med J 1974; 2: 730.
108. Jain RC, Vyas CR. Garlic in alloxan-induced diabetic rabbits. Am J Clin Nutr 1985; 28: 684-5.
109. Augusti KT, Mathew PT. Effect of allicin on certain enzymes of liver after a short term feeding to normal rats. Experientia 1975; 31: 148-9.
110. Begum H, Bari MA. Effect of garlic oil on the pancreas of experimental diabetes in guineapigs. Bangladesh Med Res Counc Bull 1985; 11: 64-8.
111. Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian J Exp Biol 1992; 30: 523-6.
112. Sheela CG, Kumud K, Augusti KT. Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats. Planta Med 1995; 61: 356-7.
113. Augusti KT, Sheela CG. Antiperoxide effect of S-allyl cysteine sulfoxide, an insulin secretagogue, in diabetic rats. Experientia 1996; 52: 115-20.
114. Farva D, Goji IA, Joseph PK, Augusti KT. Effects of garlic oil on streptozotocin-diabetic rats maintained on normal and high fat diets. Indian J Biochem Biophys 1986; 23: 24-7.
115. Swanston-Flatt SK, Day C, Bailey CJ, Flatt PR. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia 1990; 33: 462-4.
116. Ohaeri OC. Effect of garlic oil on the levels of various enzymes in the serum and tissue of streptozotocin diabetic rats. Biosci Rep 2001; 21: 19-24.
117. Patumraj S, Tewit S, Amatyakul S. Comparative effects of garlic and aspirin on diabetic cardiovascular complications. Drug Deliv 2000; 7: 91-6.
118. Sitprija S, Plengvidhya C, Kangkaya V, Bhuvapanich S, Tunkayoon M. Garlic and diabetes mellitus phase II clinical trial. J Med Assoc Thai 1987; 70(2): 223-7.
119. Melchinskaya EN, Popovtseva ON, Gromnatskii NI. Immunologic aspects of alisate in diabetes mellitus patients. Biull Eksp Biol Med 1997; 124: 595-7.
120. Ide N, Lau BH. Aged garlic extract attenuates intracellular oxidative stress. Phytomedicine 1999; 6: 125-31.
121. Sobenin IA, Maksumova MA, Slavina ES, Balabolkin MI, Orekhov AN. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. Atherosclerosis 1994; 105: 159-63.
122. Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. The clinical and public health implications for the prevention and control of cardiovascular diseases. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats. Tex Heart Inst J. 2007; 34(1): 11-8.
123. Madjid M, Miller CC, Zarubaev VV, et al. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. 3rd. Eur Heart J 2007; 28(10): 1205-10.
124. Rossiyskiy DM. Garlic (Allium sativum) and its clinical use. Klin Med (Mosk) 1933; 6: 315-7.
125. Margolina MI. The experience in the treatment of empyetic processes in lungs with phytoncides from garlic. Vrach Delo (Mosk) 1948; 10: 727.
126. Bulatov PK, Zlydnikov DM, Fedoseev GB, Khan F. The use of garlic phytoncides in the treatment of patients with different inflammatory diseases of the respiratory organs. Sov Med (Mosk) 1965; 28: 86-90.
127. Nagai K. Effect of garlic extract in prevention of virus infections. Kansenshogaku Zasshi 1973; 47: 111-5.
128. Adetumbi MA, Lau BH. Allium sativum (garlic)-a natural antibiotic. Med Hypotheses 1983; 12(3): 227-37.
129. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 2009; 52: 46-60.
130. Sytkowski PA, Kannel WB, Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990; 322: 1635-41.
131. Beaglehole R., Bonita R. Global public health: a scorecard. Lancet 2008; 372: 1988-96.
132. Bots ML, Grobbee DE. Decline of coronary heart disease mortality in The Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors. J Cardiovasc Risk 1996; 3: 271-6.
133. Ginter E. Prevention of cardiovascular diseases: the Finnish experience and current situation. Bratisl Lek Listy 1997; 98: 67-72.
134. International Task Force for Prevention of Coronary Heart Disease. Pocket guide to prevention of coronary heart disease. Grunwald, Germany: Borm Bruckmeier Verlag GmBH 2003.
135. Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Muenster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31: 1253-62.
136. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24: 1903-11.
137. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937-45.
138. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
139. Simon A, Giral P, Levenson J. Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profile. Circulation 1995; 92: 1414-21.
140. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events. a meta-analysis. Atherosclerosis 2012; 220: 128-33.
141. Peters SA, den Ruijter HM, Grobbee DE, Bots ML. Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. Circ Cardiovasc Imaging 2013; 6: 20-5.
142. Bots ML, Sutton-Tyrrell K. Lessons from the past and promises for the future for carotid intima-media thickness. J Am Coll Cardiol 2012; 60: 1599-604.
143. Robertson CM, Gerry F, Fowkes R, Price JF. Carotid intima-media thickness and the prediction of vascular events. Vasc Med 2012; 17: 239-48.
144. Negi SI, Nambi V. The role of carotid intimal thickness and plaque imaging in risk stratification for coronary heart disease. Curr Atheroscler Rep 2012; 14: 115-23.
145. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994; 14: 177-92.
146. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.
147. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87: II56-65.
148. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146: 483-94.
149. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997; 96: 1432-7.
150. Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
151. Neil HA, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and metaanalysis. J R Coll Physicians Lond 1996; 30: 329-34.
152. Koscielny J, Klussendorf D, Latza R, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999; 144: 237-49.
153. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
154. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
155. Smilde TJ, van W, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
156. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.
157. Hodis HN. Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol 1995; 25(4): S25-31.
158. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20-8.
159. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-76.
160. Zanchetti A, Rosei EA, Dal P, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term ran domized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
161. Kronmal RA, Cain KC, Ye Z, et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993; 153: 1065-73.
162. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland. Ann Intern Med 1996; 125: 713-22.
163. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993; 119: 599-605.
164. Vidyashankar S, Sambaiah K, Srinivasan K. Regression of preestablished cholesterol gallstones by dietary garlic and onion in experimental mice. Metabolism 2010; 59: 1402-12.
165. Orekhov AN, Tertov VV, Pokrovsky SN, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988; 62: 421-9.
166. Orekhov AN, Tertov VV, Kabakov AE, et al. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb 1991; 11: 316-26.
167. Kacharava AG, Tertov VV, Orekhov AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med 1993; 25: 551-5.